These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6517555)

  • 1. Effect of saturable clearance during high-dose mezlocillin therapy.
    Drusano GL; Forrest A; Fiore D; Auger F; Caplan ES
    Antimicrob Agents Chemother; 1984 Nov; 26(5):686-8. PubMed ID: 6517555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment.
    Mangione A; Boudinot FD; Schultz RM; Jusko WJ
    Antimicrob Agents Chemother; 1982 Mar; 21(3):428-35. PubMed ID: 6213190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mezlocillin pharmacokinetics after single intravenous doses to patients with varying degrees of renal function.
    Frimodt-Möller N; Maigaard S; Toothaker RD; Bundtzen RW; Brodey MV; Craig WA; Welling PG; Madsen PO
    Antimicrob Agents Chemother; 1980 Apr; 17(4):599-607. PubMed ID: 6446877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of mezlocillin in patients with kidney impairment: special reference to hemodialysis and dosage adjustments in relation to renal function.
    Brogard JM; Comte F; Spach MO; Lavillaureix J
    Chemotherapy; 1982; 28(5):318-26. PubMed ID: 6216076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of impaired renal function, hemodialysis, and peritoneal dialysis on the pharmacokinetics of mezlocillin.
    Kampf D; Schurig R; Weihermüller K; Förster D
    Antimicrob Agents Chemother; 1980 Jul; 18(1):81-7. PubMed ID: 6448024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dose on pharmacokinetics and serum bactericidal activity of mezlocillin.
    Flaherty JF; Barriere SL; Mordenti J; Gambertoglio JG
    Antimicrob Agents Chemother; 1987 Jun; 31(6):895-8. PubMed ID: 3619421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of mezlocillin and sulbactam under continuous veno-venous hemodialysis (CVVHD) in intensive care patients with acute renal failure.
    Rohde B; Werner U; Hickstein H; Ehmcke H; Drewelow B
    Eur J Clin Pharmacol; 1997; 53(2):111-5. PubMed ID: 9403281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of mezlocillin in patients with hepatobiliary dysfunction.
    Meyers BR; Srulevitch ES; Sacks HS; Hirschman SZ; Worner TM; Wormser GP; Jacobson J
    J Antimicrob Chemother; 1986 Dec; 18(6):709-13. PubMed ID: 3818496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mezlocillin pharmacokinetics in pediatric oncology patients.
    Kramer WG; Pickering LK; Culbert S; Frankel LS
    Antimicrob Agents Chemother; 1984 Jan; 25(1):62-4. PubMed ID: 6703685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mezlocillin disposition in chronic hemodialysis patients.
    Janicke DM; Mangione A; Schultz RW; Jusko WJ
    Antimicrob Agents Chemother; 1981 Nov; 20(5):590-4. PubMed ID: 6459760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of mezlocillin on the pharmacokinetics of oxacillin and dicloxacillin.
    Kampf D
    J Antimicrob Chemother; 1983 May; 11 Suppl C():25-32. PubMed ID: 6619039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent pharmacokinetics of azlocillin compared to mezlocillin.
    Bergan T; Thorsteinsson SB; Steingrimsson O
    Chemotherapy; 1982; 28(3):160-70. PubMed ID: 6212204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetics of intramuscular mezlocillin in patients with normal and impaired renal function (author's transl)].
    Brogard JM; Comte F; Kopferschmitt J; Dorner M; Lavillaureix
    Nouv Presse Med; 1982 Feb; 11(5 Pt 2):340-6. PubMed ID: 6460973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonlinear mezlocillin kinetics due to dose-dependent metabolism.
    Gundert-Remy U; Hildebrandt R; Stiehl A; Weber E
    Clin Pharmacol Ther; 1983 May; 33(5):656-62. PubMed ID: 6220858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of acylureidopenicillin pharmacokinetics.
    Bergan T
    Scand J Infect Dis Suppl; 1981; 29():33-48. PubMed ID: 7031864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developmental pharmacokinetics of mezlocillin in 4 newborn infants.
    Jungbluth GL; Wirth FH; Rubio TT; Janicke DM; Jusko WJ
    Dev Pharmacol Ther; 1988; 11(6):317-21. PubMed ID: 3229277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacokinetics of two multiple-dose mezlocillin regimens in normal volunteers.
    Colaizzi PA; Coniglio AA; Poynor WJ; Vishniavsky N; Karnes HT; Polk RE
    Antimicrob Agents Chemother; 1986 Nov; 30(5):675-8. PubMed ID: 3800343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mezlocillin kinetics in hepatic insufficiency.
    Bunke CM; Aronoff GR; Brier ME; Sloan RS; Luft FC
    Clin Pharmacol Ther; 1983 Jan; 33(1):73-6. PubMed ID: 6217018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kidney function of pyelonephritis patients with impaired renal function treated with mezlocillin.
    Lewandowski A; Kozaczek W; Orlowski T; Weuta H
    Arzneimittelforschung; 1986 Jul; 36(7):1148-50. PubMed ID: 3768087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetics of intravenous mezlocillin in patients with normal and impaired renal function (author's transl)].
    Cano JP; Rigault JP; Gevaudan MJ; Saingra S; Murisasco A; Charpin J
    Nouv Presse Med; 1982 Feb; 11(5 Pt 2):335-9. PubMed ID: 6460972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.